PEPCID COMPLETE Drug Patent Profile
✉ Email this page to a colleague
When do Pepcid Complete patents expire, and when can generic versions of Pepcid Complete launch?
Pepcid Complete is a drug marketed by J And J Consumer Inc and is included in one NDA.
The generic ingredient in PEPCID COMPLETE is calcium carbonate; famotidine; magnesium hydroxide. There are two hundred and eighty-two drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the calcium carbonate; famotidine; magnesium hydroxide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PEPCID COMPLETE?
- What are the global sales for PEPCID COMPLETE?
- What is Average Wholesale Price for PEPCID COMPLETE?
Summary for PEPCID COMPLETE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 71 |
Clinical Trials: | 35 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PEPCID COMPLETE |
What excipients (inactive ingredients) are in PEPCID COMPLETE? | PEPCID COMPLETE excipients list |
DailyMed Link: | PEPCID COMPLETE at DailyMed |
Recent Clinical Trials for PEPCID COMPLETE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ohio State University Comprehensive Cancer Center | Phase 2/Phase 3 |
United States Department of Defense | Phase 2 |
Leidos Life Sciences | Phase 2 |
Pharmacology for PEPCID COMPLETE
Drug Class | Histamine-2 Receptor Antagonist |
Mechanism of Action | Histamine H2 Receptor Antagonists |
Paragraph IV (Patent) Challenges for PEPCID COMPLETE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
PEPCID COMPLETE | Chewable Tablets | calcium carbonate; famotidine; magnesium hydroxide | 800 mg/10 mg/ 165 mg (OTC) | 020958 | 1 | 2004-11-01 |
US Patents and Regulatory Information for PEPCID COMPLETE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
J And J Consumer Inc | PEPCID COMPLETE | calcium carbonate; famotidine; magnesium hydroxide | TABLET, CHEWABLE;ORAL | 020958-001 | Oct 16, 2000 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PEPCID COMPLETE
International Patents for PEPCID COMPLETE
See the table below for patents covering PEPCID COMPLETE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 4650697 | ⤷ Sign Up | |
Greece | 67011 | ⤷ Sign Up | |
Portugal | 1019066 | ⤷ Sign Up | |
Italy | 8067346 | ⤷ Sign Up | |
Japan | S565469 | NOVEL AMIDINE DERIVATIVE AND ITS PREPARATION | ⤷ Sign Up |
Mexico | 7292 | ⤷ Sign Up | |
Sweden | 8001691 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PEPCID COMPLETE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2365988 | 2018C/006 | Belgium | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM OF EERDER WELK ZOUT OF AFGELEIDE ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
2957286 | CA 2018 00043 | Denmark | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
2957286 | 132019000000021 | Italy | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM E QUALSIASI SUO SALE O DERIVATO(VELTASSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1179, 20170721 |
2365988 | CA 2018 00006 | Denmark | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
2957286 | SPC/GB19/003 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTERED: UK EU/1/17/1179/001(NI) 20170721; UK EU/1/17/1179/002(NI) 20170721; UK EU/1/17/1179/003(NI) 20170721; UK EU/1/17/1179/004(NI) 20170721; UK EU/1/17/1179/005(NI) 20170721; UK EU/1/17/1179/006(NI) 20170721; UK EU/1/17/1179/007(NI) 20170721; UK EU/1/17/1179/008(NI) 20170721; UK EU/1/17/1179/009(NI) 20170721; UK PLGB 50784/0002-0001 20170721; UK PLGB 50784/0003-0001 20170721; UK PLGB 50784/0004-0001 20170721 |
0720599 | 300689 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
2365988 | LUC00061 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM ET TOUS LES SELS ET DERIVES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |